ArticleNPJ precision oncology2021
Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes.
Article in NPJ precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Results of a phase I/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (Bria-IMT) in metastatic breast cancer.Human vaccines & immunotherapeutics · 2024Trial
- Monitoring PD-L1 Expression on Circulating Tumor-Associated Cells in Recurrent Metastatic Non-Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy.JCO precision oncology · 2022Trial
- Molecular Deconvolution of Circulating "Other Cells": A Reliable Predictive Marker of Therapy Response and Survival in Neuroendocrine Tumor Patients ReceivingCancer medicine · 2026Article
- Peripheral TERT- positive leukocytes as a biomarker of the local and systemic immune failure in early-stage lung adenocarcinoma progression.Molecular biomedicine · 2025Article
- Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer.Cellular and molecular life sciences : CMLS · 2025Article
- Cancer-associated macrophage-like cells as a prognostic biomarker in solid tumors.The journal of liquid biopsy · 2024Review
- Prospects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers.Frontiers in molecular biosciences · 2024Review
- Article
- Cancer associated macrophage-like cells in metastatic renal cell carcinoma predicts for poor prognosis and tracks treatment response in real time.Scientific reports · 2023Article
- Circulating tumour cells in gastrointestinal cancers: food for thought?British journal of cancer · 2023Review
- Cancer-associated Macrophage-like Cells in Patients with Non-metastatic Adenocarcinoma of the Esophagus - Cytomorphological Heterogeneity.Journal of Cancer · 2023Article
- Micronuclei in Circulating Tumor Associated Macrophages Predicts Progression in Advanced Colorectal Cancer.Biomedicines · 2022Article
- Article
- Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer.International journal of molecular sciences · 2022Article
- CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome.Breast cancer research : BCR · 2022Article
- Hybrid/Atypical Forms of Circulating Tumor Cells: Current State of the Art.Biochemistry. Biokhimiia · 2022Review
- Clinical Applications of Cancer-Associated Cells Present in the Blood of Cancer Patients.Biomedicines · 2022Review
- Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells.International journal of molecular sciences · 2022Review
- CXCR4 expression in tumor associated cells in blood is prognostic for progression and survival in pancreatic cancer.PloS one · 2022Article
- Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes.NPJ precision oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is notoriously difficult to diagnosis and properly stage resulting in incorrect primary treatment. Diagnostic and prognostic biomarkers are desperately needed to more accurately stage patients and select proper treatments. Recently, a newly discovered circulating stromal cell, i.e. cancer associated macrophage-like cell (CAML), was found to accurately identify solid cancers and predict for worse prognosis. In this pilot study, blood samples were procured from 63 PC patients prior to start of therapeutic intent. CAMLs were found in 95% of samples tested, with ≥12 CAMLs/7.5 mL and ≥50 µm CAMLs both predicting for advanced pathological stage and progression free survival. These data suggest that CAML assessment prior to treatment of PC predicts patients with under-staged disease and with more aggressive PC less likely to respond to standard of care treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.